Using Heavy Water to Study Cell Dynamics in Parkinson's Disease



Status:Completed
Conditions:Parkinsons Disease, HIV / AIDS, Neurology
Therapuetic Areas:Immunology / Infectious Diseases, Neurology
Healthy:No
Age Range:18 - Any
Updated:5/5/2014
Start Date:April 2009
End Date:February 2015
Contact:Julia Peterson
Email:petersonj@sfgh.ucsf.edu
Phone:415-206-3762

Use our guide to learn which trials are right for you!

Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases

This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for
biomarker studies of diseases of the brain and spinal cord, that, together, are also called
the central nervous system (CNS). Heavy water, also called deuterated water or D20, is the
same as normal drinking water except the hydrogen atoms have been replaced by deuterium, a
naturally occurring isotope of hydrogen. In particular, this study will use heavy water to
define: 1) The rate of immune cell proliferation (growth) in the cerebrospinal fluid (CSF)
compared to blood. This study will be examining a particular type of immune cell called T
lymphocytes. 2) This study will also examine selected molecules generated by nerve cells of
the CNS to understand their rate of secretion and turnover in healthy control participants,
HIV-1-infected participants and participants with a non-HIV-related neurodegenerative
disease such as Parkinson's disease (PD).

This study will involve the administration of heavy water orally for either seven days, 12
days or six weeks. Measurements will be taken by lumbar puncture (LP, also known as a
spinal tap). Blood (approximately five tablespoons per visit) will also be obtained at each
of the lumbar puncture appointments.

If this method can be used to establish the rates of immune cell turnover and the production
rates of neuronal molecules using cerebrospinal fluid, it will provide unique data that is
important to understand chronic neurodegenerative conditions, like PD, and to measure
responses to targeted therapies.

Hypothesis:

1. D2O, administered orally, can be used to measure the proliferation rates of CSF T cells
(and, eventually, of their major phenotypic subsets).

2. D2O can be used to assess the turnover and production rates of CNS constituents that
are normally or pathologically shed or secreted into the CSF, including (eventually):
cargo molecules transported specifically in neurons in the CNS, such as chromogranin-A
and -B, neuregulin-1 (specifically the extracellular secreted ectodomain of neuronal
differentiation factor (NDF) isoform type α1, α2, β1, and the acetylcholine receptor
inducing activity isoform (ARIA), secreted amyloid precursor protein (sAPP),
alpha-synuclein; and APP metabolites amyloid beta (Aβ) 41 and 42.


Inclusion Criteria:

- 18 years of age or older

- healthy controls with no significant medical conditions

- diagnosed HIV positive patients on or off ARVs

- diagnosed Parkinson's Disease patients

- capacity to provide informed consent

Exclusion Criteria:

- none
We found this trial at
1
site
1001 Potrero Ave
San Francisco, California 94110
(415) 206-8000
San Francisco General Hospital San Francisco General Hospital and Trauma Center (SFGH) is an essential...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials